Abstract
Background During trials that span decades, new evidence including progress in statistical methodology, may require revision of original assumptions. An example is the continued use of a constant-effect approach to analyse the mortality reduction which is often delayed in cancer-screening trials. The latter led us to re-examine our approach for the upcoming primary mortality analysis(2020) of long-term follow-up of the United Kingdom Collaborative Trial of Ovarian Cancer Screening (LTFU UKCTOCS), having initially(2014) used the proportional hazards(PH) Cox-model.
Methods We wrote to 12 experts in statistics/epidemiology/screening-trials, setting out current evidence, importance of pre-specification, previous mortality analysis (2014) and three possible choices for the follow-up analysis (2020) of the mortality outcome - (A)all data(2001-2020) using the Cox-model(2014) (B)new data(2015-2020) only (C)all data(2001-2020) using a test that allows for delayed effects.
Results Of 11 respondents, eight supported changing the 2014-approach to allow for a potential delayed effect (optionC), suggesting various tests while three favoured retaining the Cox-model (optionA). Consequently, we opted for the Versatile test introduced in 2016 which maintains good power for early, constant or delayed effects. We retained the Royston-Parmar model to estimate absolute differences in disease-specific mortality at 5,10,15 and 18 years.
Conclusions The decision to alter the follow-up analysis for the primary outcome on the basis of new evidence and using new statistical methodology for long-term follow-up is novel and has implications beyond UKCTOCS. There is an urgent need for consensus building on how best to design, test, estimate and report mortality outcomes from long-term randomised cancer screening trials.
Trial registration: (ISRCTN22488978, Registration date: 6/4/2000)
Competing Interest Statement
UM has stocks in Abcodia Ltd. awarded to her by UCL. SJS and IJJ are co-inventors of the Risk of Ovarian Cancer Algorithm (ROCA) that has been licensed to Abcodia Ltd by Massachusetts General Hospital (MGH) and Queen Mary University of London (QMUL). IJJ has a financial interest in Abcodia. Ltd as a shareholder and director. IJJ and SJS are entitled to royalty payments via MGH and QMUL from any commercial use of the ROCA. All other authors declare no competing interests.
Clinical Trial
ISRCTN22488978
Clinical Protocols
http://ukctocs.mrcctu.ucl.ac.uk/long-term-impact/documents/
Funding Statement
The LTFU UKCTOCS is supported by National Institute for Health Research (NIHR HTA grant 16/46/01), Cancer Research UK (CRUK) and The Eve Appeal. UKCTOCS was funded by Medical Research Council (G9901012 and G0801228), CRUK (C1479/A2884), and the Department of Health, with additional support from The Eve Appeal. Researchers at UCL are supported by the NIHR University College London Hospitals (UCLH) Biomedical Research Centre and MRC CTU at UCL core funding (MR_UU_12023).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from the North West Multicentre Research Ethics Committee on the 21st June 2000; MREC Reference 00/8/34. Site-specific approval was obtained from the individual Local Regional Ethics Committees of the trial centres and their adjoining Primary Care Trusts (PCT). Approval was also obtained from the Caldicott Guardians (data controllers) of each of the participating PCTs. The sponsor is University College London. Approval for follow up of the entire cohort until 31st Dec 2024 was previously granted by the same committee, currently the North West - Haydock Research Ethics Committee.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Tables 2 and Supplementary Table 1 contain comments provided by the experts.
List of abbreviations
- (UKCTOCS)
- United Kingdom Collaborative Trial of Ovarian Cancer Screening
- (LTFU UKCTOCS)
- Long-term follow-up of the United Kingdom Collaborative Trial of Ovarian Cancer Screening
- (RCT)
- Randomised controlled trial
- (RR)
- Rate ratio
- (HR)
- Hazard ratio
- (CI)
- Confidence interval
- (PH)
- Proportional hazards
- (TMC)
- Trial Management Committee
- (TSC)
- Trial Steering Committee
- (SAC)
- Scientific Advisory Committee
- (MMS)
- Multimodal group
- (USS)
- Ultrasound group
- (RP)
- Royston-Parmar model
- (NORCCAP)
- Norwegian Colorectal Cancer Prevention Trial
- (PLCO)
- Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
